Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLONG-001 enlonstobart plus nab-paclitaxel and platinum neoadjuvant study in locally advanced cervical cancer
ChiCTR2400090024Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of PBI-1308, paclitaxel, cisplatin and carboplatin in Cervical Cancer (CC), sponsored by Chinese PLA General Hospital. Primary endpoint: Pathological complete response rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
PBI-1308paclitaxelcisplatincarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400090024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090024.